These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21998182)

  • 21. HIV-associated facial lipoatrophy--review of current therapy options.
    Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH;
    Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of facial lipoatrophy via autologous fat transfer.
    Cohen G; Treherne A
    J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of lipoatrophy and aging: volume deficits in the face.
    Coleman S; Saboeiro A; Sengelmann R
    Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
    Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
    Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Objective evidence for the use of polylactic acid implants in HIV-associated facial lipoatrophy using three-dimensional surface laser scanning and psychological assessment.
    Ong J; Clarke A; White P; Johnson MA; Withey S; Butler PE
    J Plast Reconstr Aesthet Surg; 2009 Dec; 62(12):1627-35. PubMed ID: 19036657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.
    Orentreich D; Leone AS
    Dermatol Surg; 2004 Apr; 30(4 Pt 1):548-51. PubMed ID: 15056149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy.
    Leclercq P; Goujard C; Duracinsky M; Allaert F; L'henaff M; Hellet M; Meunier JP; Carret S; Thevenon J; Ngo Van P; Pialoux G
    AIDS Res Hum Retroviruses; 2013 May; 29(5):761-8. PubMed ID: 23268562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
    Malan N; Su J; Mancini M; Yang R; Wirtz V; Absalon J; McGrath D;
    AIDS Care; 2010 Jun; 22(6):677-86. PubMed ID: 20467943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
    Pavicic T; Ruzicka T; Korting HC; Gauglitz G
    J Drugs Dermatol; 2010 Jun; 9(6):690-5. PubMed ID: 20645533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contemporary surgical management of HIV-associated facial lipoatrophy.
    Funk E; Bressler FJ; Brissett AE
    Otolaryngol Head Neck Surg; 2006 Jun; 134(6):1015-22. PubMed ID: 16730549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Facial lipoatrophy: appearances are not deceiving.
    Sanches RS; Mill J; Machado AA; Donadi EA; Morais Fernandes AP
    J Assoc Nurses AIDS Care; 2009; 20(3):169-75. PubMed ID: 19427594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy.
    Rajagopalan R; Laitinen D; Dietz B
    AIDS Care; 2008 Nov; 20(10):1197-201. PubMed ID: 18608076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study.
    Mole B; Gillaizeau F; Carbonnel E; Pierre I; Brazille P; Grataloup C; Mercier S; Duracinsky M; Weiss L; Piketty C
    AIDS Res Hum Retroviruses; 2012 Mar; 28(3):251-8. PubMed ID: 21801082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
    Ramon Y; Fodor L; Ullmann Y
    Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management options for facial lipoatrophy.
    Cofrancesco J; Brown T; Martins CR
    AIDS Read; 2004 Dec; 14(12):639-40, 645-50. PubMed ID: 15619779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approaches to treatment of HIV facial lipoatrophy.
    Jones D
    Skin Therapy Lett; 2005 Nov; 10(9):5-7. PubMed ID: 16292459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.